OM1 Expands into Europe to Strengthen Support for Life Sciences with AI-Driven Real-World Evidence Solutions
OM1, a leading provider of real-world data (RWD) and AI-driven insights for life sciences, today announced its expansion into Europe to better support pharmaceutical and healthcare organizations with high-quality, AI-enhanced real-world evidence (RWE) solutions. This step marks a significant milestone in OM1’s mission to improve healthcare decision-making by providing more actionable, data-driven insights across a wider geographic area.
OM1’s expansion into Europe responds to the increasing demand for validated, AI-powered real-world data and robust observational research to guide drug development, market access, and regulatory decision-making. By establishing a stronger European presence, OM1 aims to enhance support for global life sciences companies in developing effective clinical and commercial strategies.
"OM1 has consistently been at the forefront of using AI to enrich real-world data and deliver meaningful, patient-centered insights," said Dr. Richard Gliklich, CEO and Founder of OM1. "Expanding into Europe allows us to better serve our global customers by enabling them to generate critical real-world insights that improve patient outcomes and drive commercial success.”
OM1’s European expansion builds on its success in the U.S. market and will include collaborations with leading European healthcare institutions, regulatory bodies, and biopharmaceutical companies. The company’s OM1 Aspen platform will support prospective and retrospective studies and patient registries, offering a comprehensive approach to real-world evidence generation. Its AI-powered digital phenotyping platform, PhenOM®, will enable life sciences organizations to extract deeper disease insights, refine clinical development, and accelerate regulatory and market access efforts.
"With the increasing demand for AI-driven real-world evidence solutions across Europe, OM1 is well-positioned to support life sciences organizations in navigating evolving regulatory frameworks and advancing research and commercialization," said Eric Mertz, General Manager, OM1 Europe. "This expansion allows us to deliver tailored, region-specific solutions that offer greater insights and contribute to improved patient outcomes."
For more information about OM1’s expansion into Europe and real-world evidence solutions, please email info@om1.com.
About OM1
OM1 is pioneering cutting-edge healthcare innovation through its insights-driven technology and data. It specializes in personalized medicine, evidence generation, and real-world evidence (RWE) research powered by next-generation AI platforms, deep longitudinal data, and globally recognized thought leadership. OM1 is led by a diverse group of scientists, engineers, researchers, and clinicians with over 30 years of experience in RWE.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250312318676/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial8.7.2025 06:00:00 CEST | Press release
Invivoscribe Inc., a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to support CERo Therapeutics Holdings, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms. Through this collaboration, LabPMM (Invivoscribe’s global reference laboratories) have customized their multiparametric flow cytometry (MFC) services and implemented their sensitive MFC AML MRD assay to supportCERo’s clinical trial of its lead compound, CER-1236. The trial targets Acute Myeloid Leukemia (AML) in patients who are relapsed/refractory, in remission with MRD, or newly diagnosed with TP53-mutated MDS/AML. AML is an aggressive blood cancer characterized by the rapid accumulation of abnormal myeloid cells in the bone marrow and blood, disrupting normal hematopoiesis.1 Treating AML is especially complex due to its genetic heterogeneity and the high risk of relapse. CAR-T (chime
Tigo Energy Adds Solar-Plus-Storage Portfolio in Czech Republic to Build on MLPE Success8.7.2025 06:00:00 CEST | Press release
Successful PPDS P4 protocol certification opens full range of three-phase Tigo EI Inverters and the EI Residential product suite for grid connection in second-strongest E.U. market for Tigo. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced that the Company’s entire portfolio of three-phase Tigo EI Inverters has successfully passed the certification tests for compliance with the PPDS P4 requirements in the Czech Republic. Compliance with PPDS P4, formally known as Distribution System Operation Rules, Annex 4, is a prerequisite for grid connection of solar inverters in the Czech Republic, validating the compatibility with the technical conditions defined by the European Commission and adopted by local utility companies. In the wake of the proliferation of rapid shutdown requirements across Europe, with installers in the Czech Republic deploying nearly 107MW of Tigo MLPE in 2024, Tigo products ha
Murata Launches World’s First High-Frequency Filter Using XBAR Technology for 5G, Wi-Fi 7, and Future 6G Networks8.7.2025 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has announced the mass production and commercial shipment of the world’s first*1 high-frequency filter using XBAR technology*2. Developed by combining Murata’s proprietary Surface Acoustic Wave (SAW) filter expertise with XBAR technology from Murata's subsidiary Resonant Inc., it enables the extraction of desired signals while achieving both low insertion loss and high attenuation. These features are critical for the latest wireless technologies, including 5G, Wi-Fi 6E, Wi-Fi 7, and emerging 6G technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250707682186/en/ [Murata Manufacturing Co., Ltd.] The world’s first high-frequency filter using XBAR technology The demand for reliable high-frequency communications continues to grow in response to the widespread deployment of 5G and the future development of 6G. Simultaneously, wireless local-area network (W
YES Delivers Multiple VertaCure LX Systems7.7.2025 21:34:00 CEST | Press release
Yield Engineering Systems (YES), a leading provider of process equipment for AI and HPC semiconductor applications, today announced the delivery of multiple VertaCure™ LX curing systems to one of Taiwan’s top outsourced semiconductor assembly and test (OSAT) providers. These systems will support advanced packaging processes for Edge Computing and HPC solutions, delivering critical low-temperature curing, annealing, and degassing for WLCSP, Plated Bump, and Cu Pillar applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250703001376/en/ VertaCure LX The VertaCure LX is a fully automated vacuum curing and degassing system engineered to ensure uniform temperature distribution and precise control of heating and cooling rates. This results in complete solvent removal, improved film properties, elimination of outgassing after cure, and outstanding particle performance. YES products have consistently demonstrated superior qu
Nakiki SE plans strategic realignment toward a “pure” Bitcoin treasury strategy7.7.2025 20:31:00 CEST | Press release
- Aiming to build a Bitcoin portfolio - Change of name and capital measures planned Nakiki SE (ISIN: DE000WNDL300) is planning a strategic realignment with the aim of becoming the first German listed company with a pure Bitcoin treasury strategy. A Bitcoin treasury strategy means that a company focuses its investments on Bitcoin. The course for building a Bitcoin portfolio was set today following discussions with potential investors, placing banks, and Bitcoin experts. At the annual general meeting to be held in the second half of 2025, a change of name will be proposed in addition to an adjustment of the company's purpose. In addition, discussions are being held with anchor investors to secure the funds required to finance the Bitcoin portfolio through capital increases. Language: English Company: Nakiki SE Hanauer Landstr. 204 60314 Frankfurt on the Main Germany E-mail: info@nakikifinance.com Internet: https://nakikifinance.com/ ISIN: DE000WNDL300, DE000WNDL318 WKN: WNDL30, WNDL31 Li
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom